[How to eat lemon can lose weight?

锘?

]_ Recommended diet

[How to eat lemon can lose weight?
]_ Recommended diet

Speaking of lemon weight loss, in fact, everyone should be familiar with this method, because in life, lemon is a more common fruit, and it is widely used, you can also put it in when cooking food, and wantFriends who lose weight, eating lemon is also more effective, but if you want to play a better role, you should pay attention to the correct way of eating.

The reason why lemon can achieve weight loss is because lemon vitamin D and other substances can also have good beauty and beauty effects in the body, and after these ingredients are properly formulated, it will become a substance for weight loss, so eatAt the same time, lemon can make you have more perfect skin.

But lemon is more acidic, and many people may have difficulty swallowing it, so we can eat lemon through other ways of eating. A certain kind of lemon vinegar is better. Weight loss and beauty diet can also effectively reduce dark spots and freckles., To whiten the skin, it is recommended to drink a small cup after meals. This can help digestion and let you have a more beautiful figure. Be sure to remind yourself that you cannot step on an empty stomach to avoid stomach injury.

The easiest way is to soak lemonade, which can be done by everyone. Cut the lemon into slices and put it in cold water. Make sure that the lemon cannot be put in the boiling water, because it will lose or damage himAmong the nutrients.

If you want a better taste, you can put some honey in it.

[Carrot fried chives egg shreds practice]_ carrot carrot fried chives egg shreds home _ carrot carrot fried chives egg shreds practice Daquan _ carrot carrot fried chive egg shreds how to do

The children are in a state of affairs, and they are in a state of affairs. They are all in the same place, and they are all out of the way.What’s the matter? What’s the matter? Do you think it’s a good thing?
鐜板湪缇庨鑺傜洰鐩涜锛岀浉淇′綘鍦ㄧ數瑙嗗墠闈㈣偗瀹氳壋缇′笉宸层€傞偅涔堜笅闈㈠氨缁欏ぇ瀹朵粙缁嶄竴閬撶孩钀濆崪鐐掗钁辫泲涓濓紝鑷繁鏍规嵁涓嬮潰鐨勬楠わ紝鑷繁涓€瀹氳灏濊瘯鍋氫竴涓嬨€?.绾㈣悵鍗滀袱涓€?.12 黾 ㈣ 逗 黗 咏 咏 璓 钴 咃 咾 雒 囨  銆?.21 楦 撲 銷 犲 咣 撣 逦 庢 垚 嬬 劊 劊 銆?.嬔 嬬 毊 卒 囦 笣 銆?.陌 噴 凷 鐑 雑 鈕 鹘 鍒 囧 ソ 镄 勮 怅 鍗 滀 笣 銆?.灏嗚悵鍗滀笣鐐掑崐鐢熺啛鏃讹紝璋冨叆绮剧洂锛岃挏鍙躲€?.缈荤倰鍧囧寑鍚庤皟鍏ョ敓鎶界倰鍖€锛屽啀鏀捐繘棣欒懕 铔嬩笣 鐐掑寑銆?.What’s the matter? What’s the matter? What’s the matter? What’s the matter?.绾㈣悵鍗滈钁辫泲涓濆嵆鎴愩€傜湅瀹屼笂闈㈢殑浠嬬粛锛屽ぇ瀹朵粠姝や互鍚庝笉鐢ㄧ尽鎱曞埆浜轰細鍋氱編鍛崇殑椋熺墿浜嗐€傝嚜宸变篃鍙互鍔ㄦ墜锛屾牴鎹笂闈㈢殑姝ラ鍋氫竴涓嬬孩钀濆崪鐐掗钁辫泲涓濄€?

Hengrui Medicine (600276): The company’s revenue growth enters the fast track and continues to increase research and development expenses

Hengrui Medicine (600276): The company’s revenue growth enters the fast track and continues to increase research and development expenses

Investment points: After the listing of Carelizumab, the company’s revenue growth accelerated.

The company announced the third quarter report of 2019 with operating income of 169.

450北京夜网,000 yuan, an increase of 36.

01%; net profit attributable to mother 37.

3.5 billion yuan, an increase of 28.

26%; deduct non-net profit 35.

360,000 yuan, an increase of 27.

25%.

In the third quarter, the company’s revenue was 69.

190,000 yuan, an increase of 47 in ten years.

27%; net profit attributable to mother in a single quarter is 13.

22 ppm, an increase of 31 in ten years.

96%.

After the company’s blockbuster new drug, Carelizumab, has seen its revenue and profit increase after listing, its performance is in line with market expectations.

The strength of cash flow continued to develop vigorously.

The company’s selling expenses for the first three quarters of 19 were 61.

64 ppm, an increase of 32.

78%, the sales expense ratio drops by 0 every year.

89 units.

Management costs are 15.

210,000 yuan, an increase of 52.

07%.

R & D costs are 28.

99 million yuan, an increase of 66.

97%, while the company’s R & D expenses in the third quarter were 14.

1.5 billion, the previous growth rate was 90.

93%.

The company’s abundant cash inflow has ensured that the company can invest heavily in research and development, and the continued expansion of research and development investment has also greatly supported the company’s development strategy with innovative drugs as its core revenue source.

The fourth quarter mainly focused on the negotiation of the medical insurance catalog.

The results of the new round of national medical insurance directory negotiations will be announced in November, and the company pirlotinib and 19K are expected to be selected.

According to 2017 and 2018, our calculation of the volume of drug after entering the medical insurance catalog, the company’s apatinib price cut by 37% into the medical insurance catalog, and in 2018, it achieved a 67% increase.

We expect that if Pirlotinib and 19K successfully enter the medical insurance catalog, it will contribute a strong boost to the company’s continued rapid growth in 2020.

Leading domestic pharmaceutical industry, maintain “Buy” rating.

As a leading company in the domestic pharmaceutical industry, the company continues to prove that it can still maintain rapid and stable development.

We maintain our company’s profit forecast for 2019-2021.54.

10,000 yuan, 65.

9.6 billion, 79.

41 trillion, the growth rate was 32.8%, 22.

1%, 20.

4%, corresponding to PE is 68 times, 56 times, 46 times, maintaining the “buy” level.

Risk reminder: the risk of failure of clinical research and development of innovative drugs, the risk of a sharp rise in the price of innovative drugs in medical insurance negotiations

Tianbang Shares (002124): Results bottomed out and actively paid attention to the progress of the supplementary column

Tianbang Shares (002124): Results bottomed out and actively paid attention to the progress of the supplementary column

Event: The company released its 2018 annual report and 2019 first quarter report.

The company achieved revenue of 45 in 2018.

1.9 billion, +47 a year.

63%; net profit attributable to mother -5.

72 trillion, previously 杭州夜网 318.

19%; net profit attributable to non-parents is -6.

610,000 yuan, 381 years before.

28%.

2019Q1 company achieved revenue of 12.

45 trillion, +47 a year.

64%; net profit attributable to mother -3.

350,000 yuan, an average of 1142% in ten years.

The number of pigs slaughtered has increased, and the breeding efficiency has improved in 2018.

In 2018, the company produced 216 pigs.

970,000 heads, an increase of 114% in ten years.

Affected by the non-plague situation, the average sales price of commercial pigs was 12.

17 yuan, 18 years average.

3%.

The company made full use of its technological advantages. In the first three quarters of 2018, the total cost of breeding decreased by about 6% compared with 2017, and even in the fourth quarter, the cost of breeding increased due to the embargo policy, so the total cost of breeding was 12.

87 yuan / kg for years before 20171.

8%.

In addition, the company accrued part of its inventory impairment provisions in 2018, which resulted in the suspension of the pig breeding business2.

9.3 billion.

The sluggish pig price in 2019Q1 + the cost of breeding went up, and the performance bottomed out.

The number of pigs slaughtered by the company in Q1 2019 was 76.

260 thousand heads, an increase of 79% in ten years.

The pig industry was sluggish in the first quarter, with an average sales price of 11.

17 yuan / kg, superimposed company costs upward, the company’s gross profit margin is -6.

1%, maybe 3.

3.5 billion, bottoming out.

In March 2019, the company’s average hog sales price has risen to 13.

At 34 yuan / kg, the current hog price has entered the upward channel, and the profitability of hog breeding is expected to improve after the second quarter.

Affected by the embargo policy in the first quarter of 2019, there was a situation where breeding pigs were slaughtered for fattening pigs, resulting in a reduction in productive biological assets.

In 2019, young people will enter the battlefield, and China Animal Insurance’s equity transfer will be completed.

In 2018, the company fully made a total of 4 asset impairment provisions and investment losses for China Dynamic Insurance related interests.

US $ 0.7 billion. In April 2019, the company announced that it would transfer China Mobility’s equity to the actual controller, Mr. Zhang Banghui, with a transaction price of US $ 100 million and another US $ 100 million as a security deposit. The transfer of a 40% equity transaction in Zhongyu Zhihong Investment Management CompanyThe consideration was US $ 100 million and another US $ 100 million security deposit was obtained.

In summary, the company received a total of 400 million, which can cope with the pressure of funds and ensure business development.

Outlook for 2019: Continuous expansion of pig production capacity and steady development of feed business.The company can currently breed close to 150,000 heads of sows and strive to produce more than 3 million heads vertically.

In 2019, we will continue to expand the production capacity of pig breeding and realize the initial supplementary budget of the new pig farm. It is estimated that the number of slaughtering in 2020 will reach 5.2 million heads.

In 2019, the aquatic feed business will benefit from the optimization of product structure, and the high growth of shrimp feed will maintain steady development.

Investment suggestion: The pig breeding business bottomed out and benefited from the improvement in profitability of pig prices in the second half of the year.

Expected net profit attributable to mothers in 2019/20/218.

04/25.

65/28.

80 ppm, the current market value corresponds to PE32.

0/10.

0/8.

9x, maintain “Buy” rating.

Risk reminder: Macroeconomic fluctuations, non-plague situation intensify, raw material prices fluctuate, production volume is less than expected, and pig price rises are less than expected.